Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Cephea acquired by Abbott

Cephea acquired by Abbott

17th January 2019

In 2015, Abbott offered capital and received an option to acquire Cephea Valve Technologies which it has now exercised. Cephea has designed and developed an artificial, less-invasive heart valve replacement technology to treat people with mitral valve disease which presents as regurgitation, where blood leaks backward into the heart, and stenosis, a narrowing of the valve. It is delivered through a vein in the leg, removing the need for open-heart surgery, and restoring normal blood flow across the heart.

Michael Dale, structural heart business vice president at Abbott, said: “The acquisition of Cephea builds on Abbott’s strong position in structural heart therapies and is consistent with our strategy to develop comprehensive treatments for people with mitral valve disease. Cephea’s novel approach to replace the mitral valve adds to our other catheter-based technologies and is being developed to provide an additional option for patients who suffer from this difficult-to-treat disease.”

We currently have 5 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.